Mycophenolate Mofetil

Kahan, Barry D.

doi:10.1016/b978-1-4160-3343-1.50022-0

Cited by 4 publications

(2 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, MMF is well tolerated generally even though it has some side effects. The most commonly reported adverse effects are gastrointestinal symptoms, such as diarrhea, indigestion, nausea, vomiting, abdominal pain and gastroesophageal reflux (3). Bone marrow suppression is another well known side effect.…”

Section: Introductionmentioning

confidence: 99%

Oral Ulceration an Overlooked Complication of Mycophenolate Mofetil in a Renal Transplant Recipient

Ahn

Min

et al. 2011

Korean J Transplant

View full text Add to dashboard Cite

Mycophenolate mofetil (MMF) is being widely used as a maintenance imunosuppressive therapy in renal transplant patients. Myelotoxicity and gastrointestinal symptoms are the well-known adverse effects of this immunosuppressant. However, there areexistonly two reports on oral ulceration associtated with MMF. Although oral ulcerations are not life-threatening, they may seriously affect the quality of life. We report ourthe experience of a case of a 57-year-old female patient with painful oral mucosal ulcerations that improved following MMF discontinuation.

show abstract

Section: Introductionmentioning

confidence: 99%

Oral Ulceration an Overlooked Complication of Mycophenolate Mofetil in a Renal Transplant Recipient

Ahn

Min

et al. 2011

Korean J Transplant

View full text Add to dashboard Cite

show abstract

“…Along with its general minor adverse effects such as nausea, vomiting, diarrhea, headache, and dizziness, dermatologic complications have been prominent in some patients, particularly infants who are undergoing organ transplant. 2 Here, we share our experience with a 22-month-old baby who developed severe oral ulcerations during mycophenolate mofetil therapy.…”

mentioning

confidence: 99%

Untitled

2016

Exp Clin Transplant

View full text Add to dashboard Cite

No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis

Garosi

Oreopoulos

2009

Int Urol Nephrol

View full text Add to dashboard Cite

Encapsulating peritoneal sclerosis (EPS) is drawing attention to the PD community because of its unpredictable onset and high mortality.Recently, the Scottish Renal Registry [1] has established the incidence of EPS and its correlation with PD duration in that region. The rate of EPS among patients on PD was 1.5%, with an incidence of 4.9 per 1,000 person-years. This rate is well within those reported previously (0.7-3.3%) [2][3][4][5][6][7]. Interestingly, the EPS rate increased with longer duration of PD up to 5 years (from 0% at\1 year to 8.8% at[5 to 6 years), and then decreased (5% at[6 years). The median duration of PD before EPS developed was 5.1 years. At the time of diagnosis only 26% of patients with EPS were on PD. In the remainder (74%), EPS was diagnosed after PD had been discontinued; 50% of them were diagnosed with EPS after kidney transplantation with calcineurin inhibitor-based immunosuppression.

show abstract

Mycophenolate Mofetil

Cited by 4 publications

References 149 publications

Oral Ulceration an Overlooked Complication of Mycophenolate Mofetil in a Renal Transplant Recipient

Oral Ulceration an Overlooked Complication of Mycophenolate Mofetil in a Renal Transplant Recipient

Untitled

No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis

Contact Info

Product

Resources

About